Capital Advisory Group Advisory Services’s Gyre Therapeutics GYRE Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-133	Closed	-$4K	–	296
2021 Q3	$4K	Hold	133	–	–	﹤0.01%	473
2021 Q2	$4K	Hold	133	–	–	﹤0.01%	474
2021 Q1	$5K	Hold	133	–	–	﹤0.01%	446
2020 Q4	$6K	Hold	133	–	–	﹤0.01%	416
2020 Q3	$4K	Hold	133	–	–	﹤0.01%	400
2020 Q2	$6K	Buy	+133	New	+$6.25K	﹤0.01%	353

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Capital Advisory Group Advisory Services's GYRE Position: Q4 2021 in Review

Capital Advisory Group Advisory Services sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 133 shares — an estimated $4K sold.

Capital Advisory Group Advisory Services first reported a position in GYRE in Q2 2020 and held it in 6 quarters. The position peaked at $6K in Q4 2020. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

Capital Advisory Group Advisory Services reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
Capital Advisory Group Advisory Services sold 133 Gyre Therapeutics shares in Q4 2021, an estimated $4K.
Capital Advisory Group Advisory Services first reported a position in Gyre Therapeutics in Q2 2020 and held it in 6 quarters.
Capital Advisory Group Advisory Services's Gyre Therapeutics position peaked at $6K in Q4 2020.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q4 2021, filed 15 Feb 2022.